Key takeaways
Brenzavvy (bexagliflozin) and Farxiga (dapagliflozin) are both medications in the sodium-glucose cotransporter 2 (SGLT2) inhibitor class used to treat Type 2 diabetes. They help lower blood sugar levels by preventing sugar from being reabsorbed in the kidneys, causing it to be removed through urine. However, they have some differences. Brenzavvy is only approved for Type 2 diabetes, while Farxiga is also approved to reduce the risk of hospitalization and death in adults with heart failure and chronic kidney disease. Brenzavvy is taken as a 20 mg tablet once daily, whereas Farxiga is typically started at 5 mg and can be increased to 10 mg daily. Farxiga is available in both brand-name and generic forms, making it potentially more affordable. Common side effects for both include urinary tract infections, yeast infections, and increased urination. Both medications can interact with other diabetes medications, increasing the risk of low blood sugar.
